Aduro BioTech Inc (ADRO) was Reiterated by FBR Capital to “Outperform” while Lowering the Price Target of the company shares to $ 22 from a previous price target of $30 . FBR Capital advised their investors in a research report released on May 17, 2016.
Many Wall Street Analysts have commented on Aduro BioTech Inc. Shares were Downgraded by BofA/Merrill on Mar 15, 2016 to ” Underperform” and Lowered the Price Target to $ 14 from a previous price target of $32 .FBR Capital Initiated Aduro BioTech Inc on Mar 2, 2016 to “Outperform”, Price Target of the shares are set at $30.
On the company’s financial health, Aduro BioTech Inc reported $0.04 EPS for the quarter, beating the analyst consensus estimate by $ 0.27 according to the earnings call on Mar 8, 2016. Analyst had a consensus of $-0.23. The company had revenue of $34.40 million for the quarter, compared to analysts expectations of $10.83 million. The company’s revenue was up 247.5% compared to the same quarter last year.
Aduro BioTech Inc closed down -1.78 points or -16.65% at $8.91 with 62,71,567 shares getting traded on Monday. Post opening the session at $7.5, the shares hit an intraday low of $7.26 and an intraday high of $9.3296 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Jan 11, 2016, Dirk G. Brockstedt (Sr. VP of Research and Dev.) sold 22,000 shares at $22.69 per share price. According to the SEC, on Jan 11, 2016, Gregory W Schafer (Chief Operating Officer) sold 20,000 shares at $23.58 per share price. On Jan 6, 2016, Stephen T Isaacs (President and CEO) sold 25,000 shares at $26.63 per share price, according to the Form-4 filing with the securities and exchange commission.
Aduro BioTech Inc is a United States-based clinical-stage immunotherapy company. The Company has developed or acquired technology platforms designed to activate potent and lasting immune responses against cancer: live attenuated Listeria GVAX and cyclic dinucleotides (CDNs). Aduros lead program is an immunotherapy regimen combining Listeria-based CRS-207 and GVAX Pancreas in patients with metastatic pancreatic cancer who have failed at least one therapy. Its pipeline includes CRS-207 ADU-623 ADU-214 ADU-741 CDN and STINGVAX. CRS-207 is based on Aduros Listeria platform. ADU-623 is Aduro’s first clinical bivalent Listeria-based immunotherapy. ADU-214 is a bivalent Listeria-based immunotherapy that targets both mesothelin and an EGFR mutation. CDNs are small molecules that signal through STING and induce a potent immune response. STINGVAX is the combination of CDNs and GVAX.